Novartis agreed to acquire Pikavation Therapeutics, a Synnovation subsidiary, in a deal that pays $2 billion up front for SNV4818, a mutant‑selective PI3Kα inhibitor. The deal adds a next‑generation oral PI3Kα program aimed at improving tolerability versus existing drugs such as alpelisib and positions Novartis to defend and extend its breast‑cancer franchise. Novartis said SNV4818 selectively targets mutant PI3Kα to limit wild‑type inhibition and adverse effects like hyperglycemia, enabling potential use earlier in treatment and in combinations. Synnovation’s program is in early‑stage testing with primary completion expected in 2027; remaining milestone payments of up to $1 billion are tied to development, regulatory and commercial goals. The transaction underscores continued big‑pharma interest in second‑generation isoform‑selective kinase inhibitors and follows similar buyouts in the PI3Kα space. Investors and competitors will watch tolerability and combination data closely, since safety has constrained broader adoption of first‑generation PI3Kα inhibitors.